A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

Completed · Phase 1

Conditions studied: Idiopathic Pulmonary Fibrosis (IPF)

In brief

The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278

Key facts

Study ID

NCT03981094

Run by

Bristol-Myers Squibb

People needed

22

Starts

2019-05-10

Expected to finish

2019-07-30

Last updated by the study team

2020-05-15

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Signed Informed Consent.
• Healthy participant, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.

You may not qualify if…

• Women of child bearing potentia (WOCBP), pregnant or breastfeeding.
• History of significant cardiovascular disease.
• Participants who have smoked or used smoking cessation or nicotine containing products within 3 months of the first dose of study.
• Other protocol defined inclusion/exclusion criteria could apply.

Where it is running

• PRA Health Sciences - Salt Lake — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.